Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Safety assessments included treatment-emergent adverse events (AEs), vital signs (BP and HR), bodyweight, physical examinations and laboratory parameters
Anti-kindling effect of bezafibrate, a peroxisome proliferator-activated receptors alpha agonist, in pentylenetetrazole induced kindling seizure model
Checking for signs of mold exposure, mold illness, gut infections, and histamine intolerance may uncover important pieces of your POTS puzzle and may help your recovery
Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding
Why the Reference Range Is Misleading for Post-Weight-Loss Patients The reference ranges above were developed for the general population, not specifically for post-bariatric or post-weight-loss patients
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer
US$ 24.45
US$ 26.26
US$ 25.08
US$ 28.80
US$ 22.40
US$ 22.72
